Why Avlayah Changes the Game for Denali: A Practical Long Trade on DNLI
Denali's FDA approval of Avlayah and the sale of a $195 million Rare Pediatric Disease Priority Review Voucher materially derisk near-term funding and validates the company's TransportVehicle platform. Despite a recent setback in a Parkinson's program, the combination of platform validation, improving cash runway, and low leverage argues for a bull…